Valion Bio, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Form 8-K filed 2026-08-06 discloses entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02) as of 2026-07-31. Specific counterparty names, dollar amounts, share counts, pricing, and transaction terms are not provided in the filing header or accessible summary—the full document text is required to determine materiality and structure.
Why this rating
Material agreement + equity issuance at $4M market cap = structurally significant. Lack of disclosed terms prevents precision; assume non-dilutive strategic deal or modest financing. Moderate risk/opportunity pending details.
Extracted items
- 1.01 material agreement
- 3.02
- 8.01 other event
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.